In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
T cells and enhances immunotherapy-induced tumor regression in mice. These investigations yield insight into aPD-1 target engagement in vivo and identify specific Fc/FcγR interactions that can be modulated to improve checkpoint blockade therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Real-time in vivo imaging allows one to identify not only primary targets of immunotherapeutics (drug pharmacokinetics) (Arlauckas et al., 2017) but also how the tumor microenvironment responds to treatment (drug pharmacody namics).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Arlauckas et al., 2017
In the citing paper
“Most recently, a study revealed another unexpected resistance mechanism to anti-PD-1 therapy in mice whereby tumor-associated macrophages removed the therapeutic antibody from the surface of the T cells in vivo, thus making them once again susceptible to inhibitory signaling through the receptor.”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [114]
In the citing paper
“This phenomenon could be partially overcome by administration of Fc-receptor blocking agents prior to treatment (114).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Cited by
Items 201–300 of 673
Mola, S., Pandolfo, C., Sica, A., & Porta, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186866 · Cited by 47
“have observed that TAMs capture anti-PD-1 via their Fcγ receptors, limiting its availability for tumor-infiltrating CD8+ T cells [42].”
BackgroundFan, L., Liu, J., Hu, W., Chen, Z., Lan, J., Zhang, T., Zhang, Y., Wu, X., Zhong, Z., Zhang, D., et al. (2024) · Cell Research · doi:10.1038/s41422-024-00945-0 · Cited by 49
“The recruited patients from 3 groups underwent a second ultrasound examination with an average follow-up of 3 months.”
Harber, J., Kamata, T., Pritchard, C. A., & Fennell, D. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003032 · Cited by 53
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Han, N., Baghdadi, M., Ishikawa, K., Endo, H., Kobayashi, T., Wada, H., Imafuku, K., Hata, H., & Seino, K. (2018) · Inflammation and Regeneration · doi:10.1186/s41232-018-0060-2 · Cited by 48
“resistance pathway in anti-PD-1 therapy [28].”
Checkpoints and beyond – Immunotherapy in colorectal cancer
Gutting, T., Burgermeister, E., Härtel, N., & Ebert, M. P. A. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.003 · Cited by 54
Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics
Kumar, D., Mishra, A., Lisok, A., Kureshi, R., Shelake, S., Plyku, D., Sen, R., Doucet, M., Silva, R. A. D., Mease, R. C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107982118 · Cited by 48
“Additionally, the extent and duration of target engagement of mAbs in the tumor can be significantly shorter than those measured by in vitro PD assays that fail to capture the impact of the local tumor microenvironment (TME) on mAb target engagement and PK (8).”
BackgroundZhou, Y., Ye, T., Ye, C., Wan, C., Yuan, S., Liu, Y., Li, T., Jiang, F., Lovell, J. F., Jin, H., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.07.019 · Cited by 45
“542 macrophages seize anti-PD-1 and interfere with anti-PD-1 binding to the surface of T cells, hampering the reactivation of exhausted T cells [14].”
BackgroundHaddad, A. F., Young, J. S., Gill, S. A., & Aghi, M. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.019 · Cited by 50
Floudas, C. S., Brar, G. S., Mabry‐Hrones, D., Duffy, A. G., Wood, B. J., Levy, E. B., Krishnasamy, V. P., Fioravanti, S., Bonilla, C. M., Walker, M., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.06.004 · Cited by 51
Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
Pathak, R., Pharaon, R. R., Mohanty, A. R., Villaflor, V. M., Salgia, R., & Massarelli, E. (2020) · Cancers · doi:10.3390/cancers12123851 · Cited by 51
“In addition to the above mechanisms, the influx of immunosuppressive cell populations such as Tregs, myeloid-derived suppressor cells (MDSC), and M2 polarized macrophages into the TME can itself lead to decreased effector T cell effector functions in patients receiving PD-1 blockade therapy [47].”
BackgroundMoreno-Vicente, J., Willoughby, J. E., Taylor, M. C., Booth, S. G., English, V., Williams, E. L., Penfold, C. A., Mockridge, C. I., Inzhelevskaya, T., Kim, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003735 · Cited by 50
Zhong, T., Zhang, L., Huang, Z., Pang, X., Jin, C., Liu, W., Du, J., Yin, W., Chen, N., Min, J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111722 · Cited by 53
“11 For instance, ADCC and ADCP can deplete PD-1 expressing T cells and compromise the anti-tumor efficacy of anti-PD-1 antibodies, 12,13 so many antibody drugs targeting immune checkpoints, such as nivolumab choose to use IgG4 isotype to minimize Fc-induced effector functions.”
Huang, Z., Pang, X., Zhong, T., Qu, T., Chen, N., Ma, S., He, X., Xia, D., Wang, M., Xia, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.924542 · Cited by 53
New opportunities for immunomodulation of the tumour microenvironment using chemical tools
Su, J., Li, W., & Li, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00486k · Cited by 47
Lugani, S., Halabi, E. A., Oh, J., Köhler, R. H., Peterson, H. M., Breakefield, X. O., Chiocca, E. A., Miller, M. A., Garris, C., & Weissleder, R. (2022) · Advanced Materials · doi:10.1002/adma.202208782 · Cited by 46
Self-citationMetabolite activation of tumorigenic signaling pathways in the tumor microenvironment
Low, V., Li, Z., & Blenis, J. (2022) · Science Signaling · doi:10.1126/scisignal.abj4220 · Cited by 48
Emerging Biomaterials Imaging Antitumor Immune Response
Ma, X., Zhang, M., Wang, J., Zhang, T., Xue, P., Kang, Y., Sun, Z., & Xu, Z. (2022) · Advanced Materials · doi:10.1002/adma.202204034 · Cited by 43
Frontiers in intravital multiphoton microscopy of cancer
Perrin, L., Bayarmagnai, B., & Gligorijevic, B. (2019) · Cancer Reports · doi:10.1002/cnr2.1192 · Cited by 51
Perry, A., Graffeo, C. S., Carlstrom, L. P., Raghunathan, A., Driscoll, C. L. W., Neff, B. A., Carlson, M. L., Parney, I. F., Link, M. J., & Gompel, J. J. V. (2019) · Journal of neurosurgery · doi:10.3171/2019.7.jns19879 · Cited by 43
Determinants of Resistance to Checkpoint Inhibitors
Tran, L. L., & Theodorescu, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051594 · Cited by 47
“Furthermore, it has been demonstrated that TAMs can capture anti-PD-1 monoclonal antibodies via Fcγ receptors and thereby prevent binding to CD8+ T cells [180].”
BackgroundImmunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives
Yang, M., Oh, I. Y., Mahanty, A., Jin, W., & Yoo, J. S. (2020) · Cancers · doi:10.3390/cancers12092334 · Cited by 46
“One recent report has also demonstrated TAM-mediated resistance of programmed cell death 1 (PD-1) immunotherapy, thus providing a strong rationale towards TAM targeting as a reliable approach to enhance PD-1-inhibitor treatment response [41].”
BackgroundGuo, F., Kong, W., Li, D., Zhao, G., Anwar, M., Xia, F., Zhang, Y., Ma, C., & Ma, X. (2024) · European journal of medical research · doi:10.1186/s40001-024-01897-2 · Cited by 43
“However, PD-1 − macrophages can capture PD-1 antibodies from the PD-1 + CD8 + T cell surface within minutes, limiting the reactivation of exhausted T cells and rendering them incapable of anti-tumor effects [37].”
BackgroundRole of tumor microenvironment in ovarian cancer metastasis and clinical advancements
Wang, Y., Zhu, N., Liu, J., Chen, F., Song, Y., Ma, Y., Yang, Z., & Wang, D. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06508-0 · Cited by 56
Si, P., Shevidi, S., Yuan, E. C., Yuan, K., Lautman, Z., Jeffrey, S. S., Sledge, G. W., & de la Zerda, A. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b03344 · Cited by 43
Airy beam assisted NIR-II light-sheet microscopy
Liu, P., Shi, T., Li, H., Chen, H., Huang, Y., Ma, H., Zhu, T., Zhao, R., Li, Y., Qi, X., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101628 · Cited by 44
Advancements in Cancer Immunotherapies
Roy, R., Singh, S. K., & Misra, S. (2022) · Vaccines · doi:10.3390/vaccines11010059 · Cited by 49
“It has been established that the association between Fcγ receptor (FcγR), expressed by the host bone marrow cells and Fc domain glycan of the drug, could determine the ability of PD-1-TAMs to capture anti-PD-1 drugs from the surface of T cells, leading to PD-1 inhibitor resistance [48,49].”
BackgroundAcúrcio, R. C., Scomparin, A., Conniot, J., Salvador, J. A. R., Satchi‐Fainaro, R., Florindo, H. F., & Guedes, R. C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00541 · Cited by 40
Fruhwirth, G. O., Kneilling, M., de Vries, I. J. M., Weigelin, B., Srinivas, M., & Aarntzen, E. H. J. G. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-018-1254-3 · Cited by 43
“Imaging allowed to track fluorescently labeled anti-PD-1 mAb in a mouse model of colon cancer and identified the removal of anti-PD-1 mAbs from its target T cells in a Fc receptordependent process by tumor-associated macrophages as unexpected resistance mechanism [68].”
BackgroundHarrasser, M., Gohil, S. H., Lau, H. E., Peruta, M. D., Muczynski, V., Patel, D., Miranda, E., Grigoriadis, K., Grigoriadis, A. E., Granger, D., et al. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01531-1 · Cited by 46
“Our study suggests that inducible expression of an anti-PD-1 scFv in the TME results in enhanced anti-tumor response when compared with conventional F CAR-T cells combined with systemic anti-PD-1 monoclonal antibody.”
BackgroundInfluentialFc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy
Cohen Saban, N., Yalin, A., Landsberger, T., Salomon, R., Alva, A., Feferman, T., Amit, I., & Dahan, R. (2023) · Science Immunology · doi:10.1126/sciimmunol.add8005 · Cited by 39
Spatial and molecular profiling of the mononuclear phagocyte network in Classic Hodgkin lymphoma
Stewart, B. J., Fergie, M., Young, M. D., Jones, C., Sachdeva, A., Blain, A. E., Bacon, C. M., Rand, V., Ferdinand, J. R., James, K. R., et al. (2023) · Blood · doi:10.1182/blood.2022015575 · Cited by 56
Ruggiu, M., Guérin, M. V., Corre, B., Bardou, M., Alonso, R., Russo, E., Garcia, Z., Feldmann, L., Lemaître, F., Dusséaux, M., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232104 · Cited by 43
“First, Tfh cells exhibit the highest levels of PD-1 expression in lymph nodes, which likely favors their capture of anti-PD-1 mAb in this location, where antibody diffusion is known to be limited (Arlauckas et al., 2017).”
BackgroundPan, Q., Zhao, J., Liu, L., Zhang, D., Wang, L., Hu, W., Weng, D., Xu, X. M., Li, Y., Tang, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01788-2 · Cited by 42
“26 In the study, to overcome the PD-1/PD-L1 inhibitory pathway, the autologous DC-CIK cells were in directly incubated with a low-dose of pembrolizumab to generate the PD-1 blockade-activated DC-CIK cells (i.e., PD1-T cells).”
BackgroundShahzadi, M., Rafique, H., Waheed, A., Naz, H., Waheed, A., Zokirova, F. R., & Khan, H. (2024) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355241305856 · Cited by 54
“102 discovered that macrophages present in tumors rapidly removed anti-PD-1 mAbs from T cells, reducing the effectiveness of the immune system’s cytotoxic T-cell responses.”
Molecular Imaging for Cancer Immunotherapy: Seeing Is Believing
Saeed, M., Xu, Z., Geest, B. G. D., Xu, H., & Yu, H. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00851 · Cited by 41
Shirinbak, S., Chan, R. Y., Shahani, S. A., Muthugounder, S., Kennedy, R. J., Hung, L. T., Fernández, G. E., Hadjidaniel, M. D., Moghimi, B., Sheard, M. A., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1838140 · Cited by 46
Li, Y., Liu, H., Zhao, Y., Yue, D., Chen, C., Li, C., Zhang, Z., & Wang, C. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14108 · Cited by 43
Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer
Wierstra, P. J., Sandker, G. W., Aarntzen, E. H. J. G., Gotthardt, M., Adema, G. J., Bussink, J., Raavé, R., & Heskamp, S. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0078-z · Cited by 39
Macrophage regulation of graft-vs-host disease
Hong, Y., Wan, B., & Li, X. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i10.1793 · Cited by 38
Jie, C., Li, R., Cheng, Y., Wang, Z., Wu, Q., & Xie, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1122352 · Cited by 40
“In addition, Immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) have the ability to promote tumor immune escape (104, 105).”
BackgroundLi, H., Yu, M., Zhong, L., Feng, S., Xu, Y., Tang, L., Wu, C. J., Zhang, X., Gu, L., Diao, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1162032 · Cited by 43
“High TAM infiltration is strongly associated with poor tumor survival and may hijack anti-PD1 antibodies, leading to immunotherapy resistance (9, 10).”
BackgroundMechanisms of Resistance to Checkpoint Blockade Therapy
Shi, H., Lan, J., & Yang, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_5 · Cited by 40
Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy
Coleman, M. F., Cozzo, A. J., Pfeil, A. J., Etigunta, S. K., & Hursting, S. D. (2020) · Cancers · doi:10.3390/cancers12040852 · Cited by 39
“TAMs further maintain tumor immunosuppression by taking up and degrading anti-PD1 antibodies [65].”
BackgroundRecent advances in intravital microscopy for investigation of dynamic cellular behavior in vivo
Choo, Y. W., Jeong, J., & Jung, K. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.7.069 · Cited by 41
Deng, R., Lü, J., Liu, X., Peng, X., Wang, J., & Li, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s274913 · Cited by 39
Macrophages as a Potential Immunotherapeutic Target in Solid Cancers
Mishra, A. K., Banday, S., Bharadwaj, R., Ali, A., Rashid, R., Kulshreshtha, A., & Malonia, S. K. (2022) · Vaccines · doi:10.3390/vaccines11010055 · Cited by 39
“Further, a blockade of Fcγ receptors before PD-1 antibody treatment showed prolonged binding of anti-PD-1 antibodies and CD8+ T-cells infiltration [91].”
BackgroundImmune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers
Veenstra, R., Kostine, M., Cleton-Jansen, A., de Miranda, N. F. C. C., & Bovée, J. V. M. G. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.128 · Cited by 41
Lippert, A. H., Paluch, C., Gaglioni, M., Vuong, M. T., McColl, J. T., Jenkins, E. M., Fellermeyer, M., Clarke, J., Sharma, S., da Silva, S. M., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.007 · Cited by 36
An iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axis
Folkert, I. W., Arocho, W. A. M., To, T. K. J., Devalaraja, S., Molina, I. S., Shoush, J., Mohei, H., Zhai, L., Akhtar, M. N., Kochat, V., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20230420 · Cited by 40
“Importantly, tumor-associated macrophages (TAMs) often drive resistance to current modalities of cancer immunotherapy, including immune checkpoint blockade (DeNardo and Ruffell, 2019; Arlauckas et al., 2017).”
Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
Vargas, T. R., & Apétoh, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01181 · Cited by 43
Using curcumin to turn the innate immune system against cancer
Mukherjee, S., Baidoo, J., Fried, A., & Banerjee, P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113824 · Cited by 37
Lacal, P. M., Atzori, M. G., Ruffini, F., Scimeca, M., Bonanno, E., Cicconi, R., Mattei, M., Bernardini, R., D’Atri, S., Tentori, L., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104957 · Cited by 39
Soyama, T., Sakuragi, A., Oishi, D., Kimura, Y., Aoki, H., Nomoto, A., Yano, S., Nishie, H., Kataoka, H., & Aoyama, M. (2021) · Translational Oncology · doi:10.1016/j.tranon.2020.101005 · Cited by 36
Screening for new macrophage therapeutics
Rodell, C. B., Koch, P. D., & Weissleder, R. (2019) · Theranostics · doi:10.7150/thno.34421 · Cited by 35
“Microscopy based assays have been developed to quantitate the activity of CD8+ T cells, including how TAMs repress their cytotoxicity [61, 62], as well as how macrophages contribute to checkpoint blockade resistance through disadvantageous antibody uptake [37].”
MethodSelf-citationWan, L., Wu, C., Luo, S., & Xie, X. (2022) · Disease Markers · doi:10.1155/2022/3610038 · Cited by 44
Fang, C., Peng, Q., Li, X., Qu, X. D., Qiao, Z., Yin, B., Xiao, L., Chen, Y., Dong, X., Cai, L., et al. (2025) · Advanced Materials · doi:10.1002/adma.202512230 · Cited by 38
Immune Checkpoint Blockade – How Does It Work in Brain Metastases?
Lorger, M., Andreou, T., Fife, C. M., & James, F. R. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00282 · Cited by 40
Recent progress in the molecular imaging of therapeutic monoclonal antibodies
He, K., Zeng, S., & Qian, L. (2020) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2020.07.006 · Cited by 36
de Groot, A. E., Myers, K. V., Krueger, T. E. G., Brennen, W. N., Amend, S. R., & Pienta, K. J. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100830 · Cited by 37
“While macrophages can be stimulated by their environment to adopt different phenotypes, the majority of TAMs are polarized towards a phenotype that promotes cancer progression and confers treatment resistance [1 , 6 , 8-14] .”
BackgroundJames, J. L., Taylor, B. C., Axelrod, M. L., Sun, X., Guerin, L. N., Ericsson, P. I. G., Wang, Y., Sanchez, V. M., Fahey, C. C., Sanders, M. E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007736 · Cited by 34
The role of macrophages during breast cancer development and response to chemotherapy
Tao, S., Zhao, Z., Zhang, X., Guan, X., Wei, J., Yuan, B., He, S., Zhao, D., Zhang, J., Liu, Q.-D., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02348-0 · Cited by 33
Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy
Wang, S. J., Li, R., Ng, T. S. C., Luthria, G., Oudin, M. J., Prytyskach, M., Köhler, R. H., Weissleder, R., Lauffenburger, D. A., & Miller, M. A. (2020) · Science Advances · doi:10.1126/sciadv.aaz8521 · Cited by 36
“All individuals gave written informed consent to participate, and the study was approved by the institutional review boards and conducted in accordance with the human experimentation guidelines of the Massachusetts General Hospital.”
Self-citationDisrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity
Anderson, T. S., McCormick, A. L., Piersall, S. L., Okpalanwaka, I. F., & Lowe, D. B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.009 · Cited by 37
Zhao, L.-P., Hu, J.-H., Hu, D., Wang, H., Huang, C.-G., Luo, R., Zhou, Z.-H., Huang, X., Xie, T., & Lou, J.-S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112949 · Cited by 37
Yu, Y., Xie, B., Liu, X., Ye, J., Zhong, Z., & Zhang, X. (2023) · ACS Nano · doi:10.1021/acsnano.3c02126 · Cited by 33
Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
Cheng, C., Zhuge, L., Xiao, X., Luan, S., & Yuan, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.955163 · Cited by 34
“More interestingly, TAMs were found to sabotage the combination of ICI with its target by capturing PD−1 antibody from T cell surface, preventing reactivation of dysfunctional T cells (29).”
BackgroundLi, Z., Duan, D., Li, L., Peng, D., Ming, Y., Ni, R., & Liu, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1382256 · Cited by 44
Fu, Y., Guo, X., Sun, L., Cui, T., Wu, C., Wang, J., Liu, Y., & Liu, L. (2024) · eLife · doi:10.7554/elife.95009 · Cited by 39
“Arlauckas et al., 2017 found that TAM populations expressing high levels of Fc γ receptors can sequester immune checkpoint blockers, preventing their pharmacological interaction with their targets, thus contributing to the development of resistance.”
BackgroundNg, T. S. C., Gunda, V., Li, R., Prytyskach, M., Iwamoto, Y., Köhler, R. H., Parangi, S., Weissleder, R., & Miller, M. A. (2020) · Radiology · doi:10.1148/radiol.2020201791 · Cited by 35
“Fluorophore-conjugated nanoparticles (17) and antibodies (10) were prepared as previously described.”
BackgroundMethodSelf-citationA Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer
Huang, J., Agoston, A. T., Guo, P., & Moses, M. A. (2020) · Advanced Science · doi:10.1002/advs.202002852 · Cited by 34
MYD88 Is a Potential Prognostic Gene and Immune Signature of Tumor Microenvironment for Gliomas
Guo, Q., Xiao, X., & Zhang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.654388 · Cited by 35
“Their abundance in tumors is, therefore, associated with the survival of the patients (44, 45).”
BackgroundLi, X., Zhu, S., Yin, P., Zhang, S., Xu, J., Zhang, Q., Shi, S., & Zhang, T. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1971797 · Cited by 32
“This may be rapidly followed by PD-1-TAMs capture of the anti-PD1 Ab from the surface of the T cell, which thereby reduces its effectiveness (Arlauckas et al., 2017).”
BackgroundAtukorale, P. U., Moon, T. J., Bokatch, A. R., Lusi, C. F., Routhier, J. T., Deng, V. J., & Karathanasis, E. (2022) · Nanoscale · doi:10.1039/d1nr06577g · Cited by 34
Intravital microscopy for real-time monitoring of drug delivery and nanobiological processes
Momoh, J., Kapsokalyvas, D., Vogt, M., Hak, S., Kiessling, F., van Zandvoort, M., Lammers, T., & Sofias, A. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114528 · Cited by 33
Wang, F., Yang, M., Luo, W., & Zhou, Q. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.002 · Cited by 42
LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects
Liao, H.-W., Garris, C., Pfirschke, C., Rickelt, S., Arlauckas, S. P., Siwicki, M. R., Köhler, R. H., Weissleder, R., Sundvold‐Gjerstad, V., Sveinbjørnsson, B., et al. (2019) · Cell Stress · doi:10.15698/cst2019.11.204 · Cited by 31
“Intravital imaging To analyze tumors’ vascular integrity following LTX-315 injection, mice were anesthetized and dorsal skin-fold window chambers were installed as previously described [28, 29].”
MethodSelf-citationTumor-associated myeloid cells provide critical support for T-ALL
Lyu, A., Triplett, T., Nam, S. H., Hu, Z., Arasappan, D., Godfrey, W. H., Ames, R. Y., Sarang, A., Selden, H. J., Lee, C., et al. (2020) · Blood · doi:10.1182/blood.2020007145 · Cited by 30
Ning, J., Ye, Y., Shen, H., Zhang, R., Li, H., Song, T., Zhang, R., Liu, P., Chen, G., Wang, H., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101505 · Cited by 38
Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors
Berland, L., Gabr, Z., Chang, M., Ilié, M., Hofman, V., Rignol, G., Ghiringhelli, F., Mograbi, B., Rashidian, M., & Hofman, P. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1384121 · Cited by 34
Nobis, M., Warren, S. C., Lucas, M. C., Murphy, K. J., Herrmann, D., & Timpson, P. (2018) · Journal of Cell Science · doi:10.1242/jcs.206995 · Cited by 32
“For example, treatment of colorectal cancer, lung cancer and melanoma xenograft models with fluorescently labelled anti-PD1 (PD1 is also known as PDCD1) showed that TAMs take up antiPD1 from the surface of cytotoxic T-cells (CTLs), which is mediated by FCγ receptors (Fig.”
BackgroundMethodInfluentialNoninvasive imaging in cancer immunotherapy: The way to precision medicine
Du, Y., Qi, Y., Jin, Z., & Tian, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.08.009 · Cited by 30
Wen, D., Liang, T., Chen, G., Li, H., Wang, Z., Wang, J., Fu, R., Han, X., Ci, T., Zhang, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202206001 · Cited by 32
Habib, S., Osborn, G., Willsmore, Z. N., Chew, M. W., Jakubow, S., Fitzpatrick, A., Wu, Y., Sinha, K., Lloyd-Hughes, H., Geh, J. L. C., et al. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2326626 · Cited by 35
“Time-lapse intra-vital imaging studies in mouse models of anti-PD-1 responsive cancers, have shown that macrophages uptake anti-PD-1 mAbs from the surface of T cells [99], reducing their efficacy, an unhelpful consequence of mAbs binding the high affinity FcRs on these macrophages.”
BackgroundImmunoPET Imaging of TIM‐3 in Murine Melanoma Models
Wei, W., Jiang, D., Lee, H. J., Engle, J. W., Akiba, H., Liu, J., & Cai, W. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000018 · Cited by 33
Immunotherapy in melanoma: advances, pitfalls, and future perspectives
Sorino, C., Iezzi, S., Ciuffreda, L., & Falcone, I. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1403021 · Cited by 39
Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion
Bertino, P., Premeaux, T. A., Fujita, T., Haun, B. K., Marciel, M. P., Hoffmann, F. W., Garcia, A. L., Yiang, H., Pastorino, S., Carbone, M., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1601482 · Cited by 30
“A second study demonstrated that macrophages also express PD1 on their surface, which impairs their phagocytic activity.(42,43) Moreover, another recent report suggested that durable regression of established tumors requires concurrent immunotherapy with four distinct agents, which target complementary aspects of inna…”
BackgroundAsiry, S., Kim, G., Filippou, P. S., Sanchez, L. R., Entenberg, D. R., Marks, D. K., Oktay, M. H., & Karagiannis, G. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654877 · Cited by 31
Zhao, J., Yang, Z., Tu, M., Meng, W., Gao, H., Li, M. D., & Li, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.608641 · Cited by 34
“The second-highest correlation was found between SLC1A5 expression and CD86, a marker gene of tumor-associated macrophages with the ability to capture PD1-targeting antibodies on its surface and consequently limiting immunotherapeutic efficacy (59).”
BackgroundInnate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues
Fan, T. W. ‐., Higashi, R. M., Song, H., Daneshmandi, S., Mahan, A. L., Purdom, M. S., Bocklage, T. J., Pittman, T. A., He, D., Wang, C., et al. (2021) · eLife · doi:10.7554/elife.69578 · Cited by 32
Perrino, M., Vincenzo, F. D., Cordua, N., Borea, F., Aliprandi, M., Santoro, A., & Zucali, P. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121557 · Cited by 35
The Sweet Surrender: How Myeloid Cell Metabolic Plasticity Shapes the Tumor Microenvironment
Sieow, J. L., Gun, S. Y., & Wong, S. C. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00168 · Cited by 30
Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
Fernandez-Rodriguez, L., Cianciaruso, C., Bill, R., Trefny, M. P., Klar, R., Kirchhammer, N., Buchi, M., Festag, J., Michel, S., Köhler, R. H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006714 · Cited by 29
Self-citationChallenges in validation of combination treatment strategies for CRC using patient-derived organoids
Benboubker, V., Ramzy, G. M., Jacobs, S., & Nowak-Sliwinska, P. M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03173-x · Cited by 32
“In the last few years, the implication of myeloid compartment on immunotherapies response have been high-lighted in several cancer types [137, 141–144], including CRC.”
BackgroundAn, C., Hu, W., Gao, J., Ju, B., Obeidy, P., Zhao, Y. C., Tu, X., Fang, W. J., Ju, L. A., & Chen, W. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c01360 · Cited by 29
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy
Tang, K., Wang, B., Yu, B., & Liu, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113967 · Cited by 30
Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies
Adams, R., Osborn, G., Mukhia, B., Laddach, R., Willsmore, Z. N., Chenoweth, A. M., Geh, J. L. C., Ross, A. D. M., Healy, C., Barber, L. D., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2127284 · Cited by 32
“anti-PD-1 antibodies could target PD-1-expressing effector T cells.(79,80) However, engineering these antibodies with Fc regions of the IgG4 isotype, it is possible that the affinity of IgG4 for the inhibitory FcγRIIb can be utilized to reduce macrophage activation.”
BackgroundLee, H., Ferguson, A. L., Quek, C. Y. J., Vergara, I. A., da Silva, I. P., Allen, R. O., Gide, T. N., Conway, J. W., Koufariotis, L. T., Hayward, N. K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2657 · Cited by 32
Adegoke, N. A., Gide, T. N., Mao, Y., Quek, C. Y. J., Patrick, E., Carlino, M. S., Lo, S., Menzies, A. M., da Silva, I. P., Vergara, I. A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007144 · Cited by 34
Zhang, X., Liu, Y., Jiang, M., Mas‐Rosario, J. A., Fedeli, S., Cao‐Milán, R., Liu, L., Winters, K. J., Hirschbiegel, C., Nabawy, A. M., et al. (2024) · Chemical Science · doi:10.1039/d3sc06431j · Cited by 29
Optical Microscopy and Coherence Tomography of Cancer in Living Subjects
Si, P., Honkala, A. T., de la Zerda, A., & Smith, B. R. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.008 · Cited by 30
“…time in the vasculature [2,23], molecularly target speci fi c cell surface markers [24,25], penetrate the cell membrane and be retained in a cell [6], or be embedded as reporter genes to continually and nondilutively generate fl uorescent proteins in cells of interest wherever they traf fi c [7,26].”
Influential
Metadata
- Authors
- Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., Weissleder, R., & Pittet, M. J.
- Affiliations
- Harvard University (US)
- Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, MA 02114, USA.
- Massachusetts General Hospital (US)
- Corresponding author
- Arlauckas, Sean P.
- Garris, Christopher S.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-05-10
- Volume
- 9
- Issue
- 389
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5734617
- OpenAlex
- W2612649234
- Cited by
- 669
- References
- 55
- Citations by year
- 2026: 50 · 2025: 57 · 2024: 76 · 2023: 75 · 2022: 84 · 2021: 98 · 2020: 87 · 2019: 62 · 2018: 50 · 2017: 29
- FWCI
- 27.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- PubMed Central (acceptedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Funders
- National Institutes of Health (award301192, 5P50CA086355, award301190, R01AI084880, award301193, R21CA190344, award301191, U54-CA151884)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-associated macrophages, anti-PD-1 therapy, immune checkpoint inhibitor resistance, T cell activation, tumor regression, in vivo imaging, target engagement
- MeSH terms
- Animals, Antibodies, Monoclonal, Cells, Cultured, Humans, Immunotherapy, Mice, Inbred C57BL, Receptors, IgG, CD8-Positive T-Lymphocytes, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.